Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.

Stratton P, Battiwalla M, Tian X, Abdelazim S, Baird K, Barrett AJ, Cantilena CR, Childs RW, DeJesus J, Fitzhugh C, Fowler D, Gea-Banacloche J, Gress RE, Hickstein D, Hsieh M, Ito S, Kemp TJ, Khachikyan I, Merideth MA, Pavletic SZ, Quint W, Schiffman M, Scrivani C, Shanis D, Shenoy AG, Struijk L, Tisdale JF, Wagner S, Williams KM, Yu Q, Wood LV, Pinto LA.

JAMA Oncol. 2020 Feb 27. doi: 10.1001/jamaoncol.2019.6722. [Epub ahead of print]

PMID:
32105293
2.

Quality of Life in Patients With Skin of Color and Chronic Graft-vs-Host Disease.

Smith ZI, Rosenstein RK, Banerjee S, Pichard DC, Pavletic SZ, Cowen EW.

JAMA Dermatol. 2020 Feb 12. doi: 10.1001/jamadermatol.2019.4857. [Epub ahead of print] No abstract available.

PMID:
32049308
3.

Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.

Goklemez S, Im AP, Cao L, Pirsl F, Steinberg SM, Curtis LM, Mitchell SA, Cowen EW, Baruffaldi J, Rose J, Mays J, Ostojic A, Holtzman NG, Hakim FT, Pavletic SZ.

Am J Hematol. 2020 Jan 5. doi: 10.1002/ajh.25717. [Epub ahead of print]

PMID:
31903638
4.

Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia.

Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, Martin PJ, Pavletic SZ, Pidala JA, Pusic I, Vogelsang GB, Wolff D, Carpenter PA.

Blood Adv. 2020 Jan 14;4(1):40-46. doi: 10.1182/bloodadvances.2019000918.

5.

Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Rosenthal EA, Ho PS, Joe GO, Mitchell SA, Booher S, Pavletic SZ, Baird K, Cowen EW, Comis LE.

Support Care Cancer. 2019 Dec 6. doi: 10.1007/s00520-019-05207-z. [Epub ahead of print]

PMID:
31811481
6.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22. Review.

PMID:
31446199
7.

Oral Complications of Chronic Graft-Versus-Host Disease.

Fall-Dickson JM, Pavletic SZ, Mays JW, Schubert MM.

J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53). pii: lgz007. doi: 10.1093/jncimonographs/lgz007.

PMID:
31425593
8.
9.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15.

PMID:
31092900
10.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

11.

Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):577-586. doi: 10.1016/j.bbmt.2018.10.011. Epub 2018 Oct 18.

12.

Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus.

Goklemez S, Curtis LM, Hawwa A, Ling A, Avila D, Heller T, Pavletic SZ.

Mayo Clin Proc Innov Qual Outcomes. 2017 Aug 2;1(2):198-201. doi: 10.1016/j.mayocpiqo.2017.06.004. eCollection 2017 Sep.

13.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Kerep AZ, Broome J, Pirsl F, Curtis LM, Steinberg SM, Mitchell SA, Cowen EW, Pichard DC, Joe GO, Comis LE, Mays JW, Datiles MB 3rd, Stratton P, Zolton J, Berger A, Hendricks J, Kenyon M, Baruffaldi J, Titarenko I, Pulanic D, Baird K, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2019 Jan;54(1):76-84. doi: 10.1038/s41409-018-0224-3. Epub 2018 Aug 8.

PMID:
30089900
14.

Amniotic membrane transplantation-a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease.

Peric Z, Skegro I, Durakovic N, Desnica L, Pulanic D, Serventi-Seiwerth R, Petricek I, Pavletic SZ, Vrhovac R.

Bone Marrow Transplant. 2018 Nov;53(11):1466-1469. doi: 10.1038/s41409-018-0140-6. Epub 2018 Aug 8. No abstract available.

PMID:
30089899
15.

Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally.

Hakim A, Cooke KR, Pavletic SZ, Khalid M, Williams KM, Hashmi SK.

Bone Marrow Transplant. 2019 Mar;54(3):383-392. doi: 10.1038/s41409-018-0266-6. Epub 2018 Jul 23. Review.

PMID:
30038355
16.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN.

Haematologica. 2018 Nov;103(11):1915-1924. doi: 10.3324/haematol.2018.195123. Epub 2018 Jun 28.

17.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial.

Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, Im A, Wolff D, Lee SJ, Greinix H, Duarte RF, Poiré X, Selleslag D, Lewalle P, Kerre T, Graux C, Baron F, Maertens JA, Dobbels F; EBMT Transplantation Complications Working party.

Haematologica. 2018 Oct;103(10):1698-1707. doi: 10.3324/haematol.2018.190777. Epub 2018 Jun 14.

18.

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.

Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.

19.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4.

20.

Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

Yalniz FF, Murad MH, Lee SJ, Pavletic SZ, Khera N, Shah ND, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1920-1927. doi: 10.1016/j.bbmt.2018.03.008. Epub 2018 Mar 14.

21.

Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft-versus-host disease.

Bojanic I, Mravak Stipetic M, Pulanic D, Desnica L, Mazic S, Golubic Cepulic B, Serventi Seiwerth R, Vrhovac R, Nemet D, Pavletic SZ.

Transfusion. 2018 Jun;58(6):1494-1499. doi: 10.1111/trf.14594. Epub 2018 Mar 14.

22.

Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.

Buxbaum NP, Robinson C, Sinaii N, Ling A, Curtis LM, Pavletic SZ, Baird K, Lodish MB.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1415-1423. doi: 10.1016/j.bbmt.2018.02.019. Epub 2018 Mar 1.

23.

Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress.

Schoemans HM, Goris K, Van Durm R, Vanbrabant K, De Geest S, Maertens J, Wolff D, Greinix H, Ruutu T, Pavletic SZ, Im A, Lee SJ, Basak GW, Duarte RF, Dobbels F; Complications and Quality of Life Working Party of the EBMT.

Bone Marrow Transplant. 2018 Apr;53(4):490-494. doi: 10.1038/s41409-017-0017-0. Epub 2018 Jan 12. No abstract available.

PMID:
29330389
24.

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Poe JC, Jia W, Su H, Anand S, Rose JJ, Tata PV, Suthers AN, Jones CD, Kuan PF, Vincent BG, Serody JS, Horwitz ME, Ho VT, Pavletic SZ, Hakim FT, Owzar K, Zhang D, Blazar BR, Siebel CW, Chao NJ, Maillard I, Sarantopoulos S.

Blood. 2017 Nov 9;130(19):2131-2145. doi: 10.1182/blood-2017-05-782466. Epub 2017 Aug 29.

25.

Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.

Curtis LM, Pirsl F, Steinberg SM, Mitchell SA, Baird K, Cowen EW, Mays J, Buxbaum NP, Pichard DC, Im A, Avila D, Taylor T, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1980-1988. doi: 10.1016/j.bbmt.2017.08.005. Epub 2017 Aug 7.

26.

Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease.

Goklemez S, Pirsl F, Curtis LM, Steinberg SM, Cowen EW, Mays JW, Kenyon M, Baruffaldi J, Hakim FT, Pavletic SZ.

Am J Hematol. 2017 Aug;92(8):E162-E164. doi: 10.1002/ajh.24768. Epub 2017 Jun 1. No abstract available.

27.

Immunotherapy in hematologic malignancies: past, present, and future.

Im A, Pavletic SZ.

J Hematol Oncol. 2017 Apr 24;10(1):94. doi: 10.1186/s13045-017-0453-8. Review.

28.

Novel targets in the treatment of chronic graft-versus-host disease.

Im A, Hakim FT, Pavletic SZ.

Leukemia. 2017 Mar;31(3):543-554. doi: 10.1038/leu.2016.367. Epub 2016 Nov 30. Review.

PMID:
27899803
29.

High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD.

Bilic E, Delimar V, Desnica L, Pulanic D, Bilic E, Bakovic M, Curtis LM, Seiwerth RS, Stipetic MM, Ceovic R, Pulanic TK, Aleric I, Milos O, Vrhovac R, Nemet D, Pavletic SZ.

Bone Marrow Transplant. 2016 Nov;51(11):1513-1517. doi: 10.1038/bmt.2016.158. Epub 2016 Jun 6. No abstract available.

30.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

31.

Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, Yan XY, Rose J, Mays JW, Dhamala S, Kapoor V, Telford W, Dickinson J, Davis S, Halverson D, Naik HB, Baird K, Fowler D, Stroncek D, Cowen EW, Pavletic SZ, Gress RE.

J Immunol. 2016 Nov 1;197(9):3490-3503. Epub 2016 Sep 30.

32.

Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way?

Lazarus HM, Pavletic SZ.

J Clin Oncol. 2016 Aug 20;34(24):2812-3. doi: 10.1200/JCO.2016.67.7344. Epub 2016 Jul 11. No abstract available.

PMID:
27400943
33.

IL-2, the next best thing in chronic GVHD therapy?

Curtis LM, Pavletic SZ.

Blood. 2016 Jul 7;128(1):13-5. doi: 10.1182/blood-2016-05-711796. No abstract available.

34.

Vitamin D levels and their associations with survival and major disease outcomes in a large cohort of patients with chronic graft-vs-host disease.

Katić M, Pirsl F, Steinberg SM, Dobbin M, Curtis LM, Pulanić D, Desnica L, Titarenko I, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):276-86.

35.

Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters.

Vukić T, Robinson Smith S, Ljubas Kelečić D, Desnica L, Prenc E, Pulanić D, Vrhovac R, Nemet D, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):266-75.

36.

Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?

Duraković N, Krečak I, Perić Z, Milošević M, Desnica L, Pulanić D, Pusic I, Kušec V, Vrhovac R, Pavletic SZ, Nemet D.

Croat Med J. 2016 Jun 30;57(3):239-46.

37.

High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease.

Čeović R, Desnica L, Pulanić D, Serventi Seiwerth R, Ilić I, Grce M, Mravak Stipetić M, Klepac Pulanić T, Bilić E, Bilić E, Milošević M, Vrhovac R, Nemet D, Pavletic SZ.

Croat Med J. 2016 Jun 30;57(3):229-38.

38.

Erratum to "Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation" [Biol Blood Marrow Transplant 16:1362-1369].

Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, Datiles MB, Hakim FT, Kleiner DE, Krumlauf MC, Pavletic SZ.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1147. doi: 10.1016/j.bbmt.2015.09.026. Epub 2015 Oct 9. No abstract available.

39.

Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.

Pirsl F, Curtis LM, Steinberg SM, Tella SH, Katić M, Dobbin M, Hsu J, Hakim FT, Mays JW, Im AP, Pulanić D, Mitchell SA, Baruffaldi J, Masuch L, Halverson DC, Gress RE, Barsony J, Pavletic SZ.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1517-1524. doi: 10.1016/j.bbmt.2016.04.012. Epub 2016 Apr 23.

40.

Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?

Perić Z, Desnica L, Duraković N, Ostojić A, Pulanić D, Serventi-Seiwerth R, Prenc E, Basak G, Vrhovac R, Pavletic SZ, Nemet D.

Croat Med J. 2016 Feb;57(1):6-15.

41.

Chronic graft-vs-host disease in 2016: a major challenge and an opportunity.

Pulanić D, Desnica L, Vrhovac R, Nemet D, Wolff D, Greinix H, Pavletic SZ.

Croat Med J. 2016 Feb;57(1):1-3. No abstract available.

42.

Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Prenc E, Pulanic D, Pucic-Bakovic M, Pezer M, Desnica L, Vrhovac R, Nemet D, Pavletic SZ.

Biochim Biophys Acta. 2016 Aug;1860(8):1615-22. doi: 10.1016/j.bbagen.2016.02.015. Epub 2016 Feb 26. Review.

43.

Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD.

Im A, Mitchell SA, Steinberg SM, Curtis L, Berger A, Baird K, Kuzmina Z, Joe G, Comis LE, Juckett M, Avila D, Baruffaldi J, Masuch L, Pirsl F, Pavletic SZ.

Bone Marrow Transplant. 2016 May;51(5):705-12. doi: 10.1038/bmt.2015.320. Epub 2016 Feb 1.

PMID:
26828906
44.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN.

J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.

45.

Phase-1/-2 study of pomalidomide in chronic GvHD.

Pusic I, Rettig MP, DiPersio JF, Bauer S, McFarland K, Gale RP, Pavletic SZ.

Bone Marrow Transplant. 2016 Apr;51(4):612-4. doi: 10.1038/bmt.2015.298. Epub 2015 Dec 14. No abstract available.

PMID:
26657832
46.

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ.

Blood. 2016 Jan 7;127(1):160-6. doi: 10.1182/blood-2015-08-662874. Epub 2015 Nov 2.

47.

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ.

Biol Blood Marrow Transplant. 2016 Apr;22(4):710-716. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22.

48.

Deciphering the Mystery: Extracorporeal Photopheresis in Graft-versus-Host Disease.

Im A, Pavletic SZ.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1861-2. doi: 10.1016/j.bbmt.2015.09.011. Epub 2015 Sep 18. No abstract available.

49.

Immunotherapy for acute leukemia.

Boyiadzis M, Whiteside TL, Pavletic SZ.

Aging (Albany NY). 2015 Jun;7(6):354-5. No abstract available.

50.

Syk and tired of current chronic GVHD therapies.

Fowler DH, Pavletic SZ.

Blood. 2015 Jun 25;125(26):3974-5. doi: 10.1182/blood-2015-05-640672.

Supplemental Content

Loading ...
Support Center